Ludwig Institute for Cancer Research Limited

Sloan-Kettering Institute for Cancer Research

Memorial Sloan Kettering Cancer Center

Other

Cornell University

Sloan-Kettering Institute

Massachusetts Institute of Technology

Commonwealth Scientific and Industrial Research Organisation

New York Blood Center, Inc.

Abbott Laboratories Corporation

Boehringer Ingelheim International Gmbh

Yale University

Washington University

Oxford University Innovation Ltd

Boehringer Ingelheim Gmbh

Lloyd J Old

Ugur Sahin

Yao-tseng Chen

Matthew J Scanlan

Elisabeth Stockert

Gerd J Ritter

Wolfgang J Rettig

Kenneth O Lloyd

Pilar Garin-Chesa

Herbert F Oettgen

Ali O Gure

Sydney Welt

Alexander Knuth

Francis Joseph Carr

Thomas Paul Wallace

Michael Pfreundschuh

Alan N Houghton

Carlos Cordon-Cardo

M Jules Mattes

Elke J&auml;ger

Richard J Cote

Ozlem Tureci

Elke Jäger

Myron R Melamed

Kunio Kitamura

Sacha Gnjatic

Solam Tsang

Knuth Alexander

Ivan Tarasovich Gout

Achim Jungbluth

Terrance Grant Johns

Junichi Sakamoto

Francisco X Real

Barbara D Williamson

Connie L Finstad

Chaitanya R Divgi

Timothy M Thomson

Philip O Livingston

Edouard Collins Nice

Kathryn Lesley Armour

Anne Murray

Leonard Cohen

George Mark

Serhiy Souchelnytskiy

Valeriy Filonenko

Ramziya Kiyamova

Beatrice Yin

Sang-Yull Lee

Samual Yeh

Willet F Whitmore

Elizabeth C Richards

John L Lewis, Jr

Carlos F Barbas, Iii

Hiroshi Yamaguchi

Timothy Edward Adams

Robert D Schreiber

Cynthia H Scanlan, Legal Representative

&Ouml;zlem T&uuml;reci

Neil H Bander

Koichi Furukawa

Berish Y Rubin

Sylvia L Anderson

Cameron Johnstone

Maria P Sanz-Moncasi

Hong Ji

R L Moritz

Mary John

Elizabeth Carswell Richards

Clarence Williams, Jr

Thierry R Boon-Falleur

Pierre Van Der Bruggen

Stefan Stevanovic

Jan Wouter Drijfhout

William Joseph Harris

Antony Wilks Burgess

Elke Jager

John Edward Park

Rainer Zimmermann

Andrew Ewart Scott

Richard John Simpson

K Dane Wittrup

Christoph Rader

Richard R Schmidt

Frank J Carr

Webster K Cavenee

Francis J Carr

Con Panousis

Karl Welte

Jorge E Galan

Anthony P Albino

Vincenzo Cerundolo

Dirk Jager

Paul B Chapman

Christoph Renner

Elizabeth Stockert

Andrew Mark Scott

Karl-Anders Karlsson

Shun-ichiro Ogata

The present invention relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.

Antibodies directed to membrane transporter NaP12b (SLC34A2) and uses thereof in cancer therapy

Membrane transporter NaPi2b (SCL34A2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy

The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806.

Specific binding proteins and uses thereof

The present invention relates to antibodies, particularly antibody 175, and fragments thereof or antibodies derived therefrom, which bind to the EGF receptor, particularly to amplified or overexpressed epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. These antibodies are useful in the diagnosis and treatment of cancer. Recombinant or hybrid antibodies having the variable region heavy or light chain sequence(s) of antibody 175 are also provided. The antibodies of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.

Monoclonal antibody 175 targeting the EGF receptor and derivatives and uses thereof

The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.

Membrane transporter NaPi2b (SCL34A2) epitope antibodies

The present invention relates generally to growth factor receptor epitope peptides, particularly EGF family receptor epitope peptides. The invention also relates to the use of the receptor peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against the receptor peptides. Methods for generating an immune response and for treatment of tumors and cancer are also provided.

Antibodies to EGF receptor epitope peptides and uses thereof

The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts.

Method for inducing cell lysis with immunogenic portions of NY-ESO-1 protein

The invention relates to the use of the type III secretion system of bacteria to stimulate immune responses against tumor antigen(s) for treating antigen-loss variant tumors. Methods are provided for stimulating and/or increasing an immune response against tumor antigens. The invention also relates to the preparation of antigen presenting cells from peripheral blood mononuclear cells using bacteria having a type III secretion system.

Methods for stimulating an immune response using bacterial antigen delivery system

The invention relates to sarcoma-associated antigens and the nucleic acid molecules that encode them. The invention further relates to the use of the nucleic acid molecules, polypeptides and fragments thereof associated with sarcoma in methods and compositions for the diagnosis and treatment of diseases, such as cancer. More specifically, the invention relates to the discovery of a novel cancer/testis (CT) antigen, NY-SAR-35.

Human sarcoma-associated antigens

Isolated nucleic acid molecules which encode immunogenic portions of NY-ESO-1 protein

The invention provides methods, compositions and kits for inducing and/or enhancing an immune response in a subject. The invention in some aspects includes polypeptide and nucleic acid molecules that induce and/or enhance an immune response. In some aspects of the invention, the polypeptide and/or nucleic acid molecules of the invention are useful to induce and/or enhance an immune response in a subject who has or is suspected of having cancer.

Method for inducing immune response to NY-CO-58

Antibodies to EGF receptor epitope peptides

Growing community of inventors

New York, NY, United States of America

Lloyd J Old